Meta-analysis on the Diagnostic Value of SDC2 Methylation in Colorectal Cancer Screening Among Chinese

Yi Wu

doi:10.62051/4v79wb06

Authors

Yi Wu

DOI:

https://doi.org/10.62051/4v79wb06

Keywords:

Colorectal cancer; Advanced colorectal adenoma; SDC2 gene methylation; Screening; Meta-analysis.

Abstract

To systematically evaluate the diagnostic value of syndecan-2 (SDC2) gene methylation status in the detection of Colorectal cancer (CRC) and advanced adenomas (AA) through meta-analysis. Databases including PubMed, Web of Science were searched from 2020 to June 14, 2024. Relevant studies were selected based on predefined inclusion and exclusion criteria. The true positive (TP), false positive (FP), false negative (FN), and true negative (TN) results were calculated for each study. The quality of the included studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. A bivariate meta-analysis model was used to pool the sensitivity, specificity, diagnostic odds ratio (DOR), positive likelihood ratio (PLR), and negative likelihood ratio (NLR), and a summary receiver operating characteristic (SROC) curve was constructed. Spearman’s correlation coefficient, Cochran-Q test, and I² test were used to evaluate heterogeneity. Sensitivity analysis was performed to explore the potential sources of heterogeneity. 24 literatures were included for meta-analysis. The pooled sensitivity was 0.77 for CRC and 0.52 for AA, and the pooled specificity was 0.93 for CRC and 0.91 for AA. The pooled PLR was 10.63 for CRC and 5.57 for AA, and the pooled NLR was 0.25 for CRC and 0.53 for AA. The DOR was 43.21 for CRC and 10.47 for AA. The SROC AUC was 0.91 for CRC and 0.83 for AA. The methylation level of the SDC2 gene in stool samples has significant diagnostic value for colorectal cancer and is considered an ideal biomarker for the early detection of this disease.

Downloads

Download data is not yet available.

References

[1] H.X. Shi, et al. Analysis of the Results of Early Screening for Colorectal Cancer in Xiamen Community from 2019 to 2021, Journal of Community Medicine. 21(11) (2023) 545-550.

[2] R.G.Zhu, et al. Analysis Report of Early Screening for Colorectal Cancer in the Tibetan Plateau Area, Tibet University, 2023. R.J. Ong, J.T. Dawley and P.G. Clem: submitted to Journal of Materials Research. (2003).

[3] X. Zhou, M. Hu, et al. Analysis of the Global and Chinese Epidemiological Status of Colorectal Cancer in 2020, Journal of Naval Medical University. (2022).

[4] S.J. Li, et al. Research Progress on Compliance and Cost-Effectiveness of Colorectal Cancer Screening Methods, Journal of Chengde Medical College. 40(1) (2023) 60-64.

[5] H. Zhao, Expression and Clinical Significance of PER1 and PER2 in Gastric Cancer Tissues, Guangzhou Medical University. (2014).

[6] Digestive Diseases Branch of Chinese Medical Association. Consensus on Prevention of Colorectal Cancer in China, Gastroenterology. (2016).

[7] Q. Kang, et al. The Significance of Septin9 Gene Methylation in Peripheral Blood Free DNA in Screening for Colorectal Cancer, Academic Annual Conference on Digestive System Diseases of Beijing Branch of Chinese Medical Association. (2014).

[8] Z.Y. Gong, et al. The Value of Fecal SDC2 Gene Methylation Detection in the Adjuvant Diagnosis of Colorectal Cancer, Laboratory Medicine. (2022).

[9] C.Y. Zhang, et al. Evaluation of Plasma Septin9 Gene Methylation Detection Performance and Its Screening Value for Colorectal Cancer Patients, Chinese Journal of Clinical Laboratory Science. (2) (2019) 4.

[10] J. Liu, et al. Analysis of Diagnostic Efficiency of Pooled Detection of CA19-9, CA72-4, CEA, PGⅠ, and PGⅡ for Gastric Cancer, Chinese Journal of Biomedical Engineering. 28(4) (2022) 7.

[11] F. Niu, et al. Stool DNA Test of Methylated syndecan-2 for the Early Detection of Colorectal Neoplasia, Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. (2017) 153.

[12] W. Cao, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020, Chinese Medical Journal. (2021).

[13] K. Selby, et al. Influence of Varying Quantitative Fecal Immunochemical Test Positivity Thresholds on Colorectal Cancer Detection: A Community-Based Cohort Study, Annals of internal medicine.169(7) (2018).

[14] J. L. Padayao, C. Dy. The prognostic ability of immune scoring system Immunoscore in patients with localized colon cancer: A systematic review and meta-analysis, Journal of Clinical Oncology. 41(16) (2023) 2565.

[15] H.Y. Wu, et al. Significance of SDC2 and SEPT9 gene methylation in feces in colorectal cancer screening and early diagnosis, China Modern Drug Application. 16 (23) (2022) 190-194.

[16] H.Y. Wu, et al. Diagnostic efficacy of combined detection of SDC2 and TFPI2 methylation in feces for colorectal cancer and precancerous lesions, Chinese Journal of Modern Medicine. 25(1) (2023) 7-12.

[17] H. Pan, et al. Value of combined detection of fecal genes SDC2 and BMP3 methylation in screening for colorectal cancer, China Medical Herald. 17 (11) (2020) 5.

[18] Y. Cai. Role and mechanism of methylation and micro-RNA-related genes in colorectal cancer screening and diagnosis, Anhui Medical University. (2024).

[19] X.C. Chen, et al. Application of stool SDC2 gene methylation detection combined with FOB, CEA and CA199 detection in early colorectal cancer screening, Chinese Journal of Anorectal Diseases.44 (03) (2024) 1-5.

[20] A. Abduresiti. The value of SDC2 gene methylation in stool in the screening and diagnosis of colorectal cancer, Central South University. (2023).

[21] L.W. Zhang, Diagnostic efficacy of stool gene SDC2 and SFRP2 methylation for colorectal cancer screening, Jinzhou Medical University. (2024).

[22] M.Z. Chu, et al. Application value of combined detection of SDC2 and TFPI2 gene methylation in early screening of colorectal cancer, Journal of Anhui Medical University. 58(4) (2023) 682-686.

[23] W.W. Jin, et al. Analysis of stool SDC2 and NDRG4 gene methylation detection in colorectal cancer screening, Journal of Hunan Normal University: Medical Science Edition. 18(6) (2021) 5.

[24] C.K. Li, et al. Application value of stool SDC2 gene methylation detection in early detection of colorectal cancer, Surgical Research and New Technology. 9 (1) (2020) 10-13.

[25] Y.Q. Li, The clinical application value of stool Syndecan2 gene methylation detection in screening colorectal cancer, Kunming Medical University. (2023).

[26] R.X. Lin, et al. Detection of SDC2 gene methylation in fecal samples for early diagnosis of colorectal cancer, Zhejiang Medical Journal. 44(23) (2022) 2531-2534.

[27] L. Long, et al. Significance of SDC2 and NDRG4 methylation in stool for colorectal cancer diagnosis, Clin Biochem. (2024).

[28] Y. Zhan, et al. The stool syndecan2 methylation test is more robust than blood tests for methylated septin9, CEA, CA19-9 and CA724: a diagnostic test for the early detection of colorectal neoplasms, Transl Cancer Res. 12(1) (2023) 65-77.

[29] L.H. Zhong, et al. The significance and relationship of detection of gut microbiota and fecal SDC2 genemethylation in colorectal cancer patients , Journal of Practical Hospital Clinic. 21(3) (2024) 116-120.

[30] Y.L. Zhang, et al. Application value of stool SDC2 gene methylation detection in screening for colorectal cancer, International Journal of Laboratory Medicine. 44(08) (2023) 961-965.

[31] Y. Wang, et al. Clinical Value of Fecal SDC2 Gene Methylation Detection inEarly Screening of Colorectal Cancer, Journal of Kunming Medical University. 44 (5) (2023) 138-143.

[32] N.J. Tan, D.Q. Zhang, Clinical value of combined gene methylation(SDC2,TFPI2 and SFRP2)in fecalspecimen for early screening of colorectal cancer, Journal of Gastroenterology and Hepatology.32 (08) (2023) 847-851.

[33] Z.Y. Gong, et al. Application value of fecal SDC2 gene methylation determination in the auxiliary diagnosis of colorectal cancer, Laboratory Medicine. (2022).

[34] T.B. Niu, et al. Application Value of Fecal SDC2 Gene Methylation Combined with CEA Detection in the Differential Diagnosis of Early Colorectal Cancer, Laboratory Medicine. (2022).

[35] Q.L. Li, J.W. Zhang, Performance verification of SDC2 and TFPI2 gene methylation combined detection reagent,International Journal of Laboratory Medicine. 44(23) (2023) 2893-2896 + 2901.

[36] Y. Dai, et al. A simplified multiplex methylated DNA testing for early detection of colorectal cancer in stool DNA, BMC Gastroenterol. Oct 622(1) (2022) 428.

[37] G. Zhao, et al. Methylated SFRP2 and SDC2 in stool specimens for Colorectal Cancer early detection: A cost-effective strategy for Chinese population, J Cancer. Mar 512(9) (2021) 2665-2672.

[38] W.C. Su, et al. Stool DNA test targeting methylated syndecan-2 (SDC2) as a noninvasive screening method for colorectal cancer, Biosci Rep. (2021).